Continued Benefit, More Toxicity With First-Line Osimertinib Plus Chemo in NCSLC
Patients with advanced EGFR-mutated NSCLC who were given osimertinib plus chemotherapy up front continue to show improved outcomes after initial progression, suggests ongoing trial data.